NEOVACS
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoi... ds). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.
NEOVACS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
1993-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.neovacs.fr
Total Employee:
11+
Status:
Active
Contact:
33 1 53 10 93 00
Email Addresses:
[email protected]
Total Funding:
44.79 M USD
Technology used in webpage:
IPv6 Pound Sterling Japanese Yen 1and1
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Piramed
Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Alpha Blue Ocean™
Alpha Blue Ocean™ investment in Post-IPO Debt - Neovacs
Bpifrance
Bpifrance investment in Post-IPO Equity - Neovacs
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - Neovacs
Truffle Capital
Truffle Capital investment in Venture Round - Neovacs
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Venture Round - Neovacs
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-10-20 | Signia Therapeutics | Neovacs investment in Series A - Signia Therapeutics | 1.3 M EUR |
| 2021-09-27 | Bio-Detection K9 | Neovacs investment in Venture Round - Bio-Detection K9 | 5 M USD |
Official Site Inspections
http://www.neovacs.fr
- Host name: 217-160-0-99.elastic-ssl.ui-r.com
- IP address: 217.160.0.99
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
